文献速递神经肿瘤

机器学习基于MRI预测胶质瘤分子标志物的系统综述与荟萃分析

Machine Learning for the Prediction of Molecular Markers in Glioma on Magnetic Resonance Imaging: A Systematic Review and Meta-Analysis.
PubMed 文献 · Neurosurgery · 2021-01-01

IDH突变在训练集中合并敏感度0.88(95%CI 0.83-0.91)、特异度0.86(95%CI 0.79-0.91),验证集敏感度0.83至0.85;MGMT启动子甲基化和1p/19q共缺失在训练集中合并敏感度与特异度介于0.76至0.83。结论认为机器学习用于术前MRI预测上述分子标志物结果有前景。

要点

  • 机器学习模型术前MRI预测IDH突变训练集敏感度0.88、特异度0.86。
  • MGMT甲基化与1p/19q共缺失训练集合并敏感度与特异度0.76至0.83。
  • 未来需多中心数据、外部验证并探索临床可行性。

核心结论

  • 机器学习应用于术前MRI在预测胶质瘤IDH突变、MGMT甲基化和1p/19q共缺失方面展现出有前景的结果。

研究设计与样本

  • 使用QUADAS-2评估方法学质量,采用双变量模型获得诊断性能估计,并用荟萃回归探索异质性。

主要发现

  • 训练集中预测IDH突变的合并敏感度为0.88(95%CI 0.83-0.91),合并特异度为0.86(95%CI 0.79-0.91)。
  • 验证集中IDH突变的合并敏感度为0.83至0.85。
  • 训练集中MGMT基因启动子甲基化和1p/19q共缺失的合并敏感度与特异度均介于0.76至0.83。
  • 数据增强的使用和MRI序列类型与异质性呈弱相关。

临床怎么用

  • 优化后的机器学习模型可能成为无创、客观的工具,捕获对临床决策重要的分子信息。

局限性

  • 未来研究应使用多中心数据、外部验证并探究机器学习模型的临床可行性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Molecular characterization of glioma has implications for prognosis, treatment planning, and prediction of treatment response. Current histopathology is limited by intratumoral heterogeneity and variability in detection methods. Advances in computational techniques have led to interest in mining quantitative imaging features to noninvasively detect genetic mutations. OBJECTIVE: To evaluate the diagnostic accuracy of machine learning (ML) models in molecular subtyping gliomas on preoperative magnetic resonance imaging (MRI). METHODS: A systematic search was performed following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines to identify studies up to April 1, 2020. Methodological quality of studies was assessed using the Quality Assessment for Diagnostic Accuracy Studies (QUADAS)-2. Diagnostic performance estimates were obtained using a bivariate model and heterogeneity was explored using metaregression. RESULTS: Forty-four original articles were included. The pooled sensitivity and specificity for predicting isocitrate dehydrogenase (IDH) mutation in training datasets were 0.88 (95% CI 0.83-0.91) and 0.86 (95% CI 0.79-0.91), respectively, and 0.83 to 0.85 in validation sets. Use of data augmentation and MRI sequence type were weakly associated with heterogeneity. Both O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation and 1p/19q codeletion could be predicted with a pooled sensitivity and specificity between 0.76 and 0.83 in training datasets. CONCLUSION: ML application to preoperative MRI demonstrated promising results for predicting IDH mutation, MGMT methylation, and 1p/19q codeletion in glioma. Optimized ML models could lead to a noninvasive, objective tool that captures molecular information important for clinical decision making. Future studies should use multicenter data, external validation and investigate clinical feasibility of ML models.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Jian A, Jang K, Manuguerra M, et al. Machine Learning for the Prediction of Molecular Markers in Glioma on Magnetic Resonance Imaging: A Systematic Review and Meta-Analysis. Neurosurgery. 2021. PMID: 33826716. doi:10.1093/neuros/nyab103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。